36822-08-9

Upstream product

• 35212-85-2 3-Amino-benzo[b]thiophene-2-carboxylic acid methyl ester 
• 34761-09-6 ethyl 3-aminobenzothiophene-2-carboxylate 
• 77287-34-4 formamide 
• 3473-63-0 formamidine acetic acid 
• 7716-66-7 3-chloro-1,2-benzisothiazole 
• 99027-28-8 methyl 3-(ethoxymethylene)amino-2-benzothiophenecarboxylate 
• 99027-29-9 3-Aminobenzothiophene-2-carboxylic acid hydrazide 
• 394-47-8 2-fluorobenzonitrile 
• 99027-30-2 3-amino<1>benzothieno<3,2-d>pyrimidin-4(3H)-one 

Downstream Products

• 36822-09-0 4-chloro-3,4-dihydrobenzo[4,5]thiophene[3,2-d]pyrimidine 
• 41873-18-1 3H-benzyl-3 benzothieno<3,2-d>pyrimidone-4 
• 1414524-15-4 N-(2-methylphenyl)benzo[4,5]thieno[3,2-d]pyrimidin-4-amine 
• 1414524-07-4 N-(2-methylbenzyl)benzo[4,5]thieno[3,2-d]pyrimidin-4-amine 
• 1414524-09-6 N-(2-methoxybenzyl)benzo[4,5]thieno[3,2-d]pyrimidin-4-amine 
• 1414524-11-0 N-(4-methoxybenzyl)benzo[4,5]thieno[3,2-d]pyrimidin-4-amine 
• 1414524-13-2 N-phenylbenzo[4,5]thieno[3,2-d]pyrimidin-4-amine 
• 41873-33-0 phenylthio-4 benzothieno<3,2-d>pyrimidine 
• 41873-38-5 phenoxy-4 benzothieno<3,2-d>pyrimidine 
• 41873-29-4 benzylthio-4 benzothieno<3,2-d>pyrimidine 
• 41873-24-9 3H-benzyl-3 benzothieno<3,2-d>pyrimidine-thione-4 

Relevant academic research and scientific papers

Synthesis method of iridium-containing complex

The invention discloses a synthesis method of an iridium-containing complex. The synthesis method is characterized in that a compound Ir (La) (Lb) 2 is prepared through one-step reaction of a substance shown in the specification and La in the presence of one or more solvents or in the absence of solvents. The synthesis method is suitable for an iridium-containing complex containing two same bidentate C-N ligands and one bidentate 1, 3-diketone, 1, 3-dithione or 1, 3-diimine ligand. Compared with the traditional synthesis method, the synthesis method has higher synthesis efficiency, can be carried out under milder reaction conditions, and can realize the synthesis of some complexes which cannot be realized by the traditional method. The iridium-containing complex prepared by the synthesis method is easier to be used in production and manufacturing of organic electroluminescent devices.

Bicarbazole containing compounds for OLED

The present disclosure generally relates to novel compounds containing carbazole and triazine with different number of phenyl units attached to its core. In particular, the disclosure relates to compositions and/or devices comprising these compounds as ho

DONOR-ACCEPTOR COMPOUNDS WITH NITROGEN CONTAINING HETEROPOLYAROMATICS AS THE ELECTRON ACCEPTOR

Disclosed is a light emitting substance that is used as an emitter in an organic light emitting diode. The light emitting substance includes a donor-acceptor compound having a high triplet energy heteropoly aromatic system. In other words, the donor-acceptor compound includes dibenzofuran, dibenzothiophene, and dibenzoselenophene that are electron acceptors and have multiple nitrogen atoms in one ring. The compound is represented by Chemical Formula 1 below.COPYRIGHT KIPO 2015

Synthesis and evaluation of apoptosis induction of thienopyrimidine compounds on KRAS and BRAF mutated colorectal cancer cell lines

Monoclonal antibodies (MoAb) and tyrosine kinase inhibitors (TKI) targeting the EGFR (Epidermal Growth Factor Receptor) pathways are currently used in colorectal cancer treatment. Despite the improvement of median overall survival, resistance is observed

PYRIDO [3',2' :4,5] THIENO [3, 2-D] PYRIMIDIN- 4 - YLAMINE DERIVATIVES AND THEIR THERAPEUTICAL USE

The present invention pertains generally to the field of therapeutic compounds, and more specifically to certain fused triaryl amine compounds of the following formula (for convenience, collectively referred to herein as "FTA compounds"), which, inter alia, inhibit LIM kinase (LIMK) activity. The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit LIMK activity, and in the treatment of diseases and conditions that are mediated by LIMK, that are ameliorated by the inhibition of LIMK activity, etc., including proliferative conditions such as cancer (e.g., breast cancer, prostate cancer, melanoma, glioma, etc.), as well as vasodilation (including, e.g., hypertension, angina, cerebral vasospasm, and ischemia following subarachnoid hemorrhage), neurodegenerative disorders, atherosclerosis, fibrosis, and inflammatory diseases (including, e.g., Crohn's disease and chronic obstructive pulmonary disease (COPD)), and glaucoma (also known as ocular hypertension).

Synthesis of [1]Benzothieno[3,2-d]pyrimidines Substituted with Electron Donating Substituents on the Benzene Ring

Various 2-fluorobenzonitriles were converted to the corresponding 3-amino[1]benzothiophenecarboxylic acid esters, which in turn were annulated with formamidine or various equivalents to produce the desired tricyclic benzothienopyrimidines. Various methoxy and nitro/amino substituants were placed on the phenyl ring, requiring several different strategies to prepare the desired benzothiophenes. Several different pyrimidone annulations were also required. The use of an electron rich 2-bromobenzonitrile in a four-step one-pot low temperature lithiation sequence to produce highly electron-rich amino[1]benzothiophenecarboxylate esters is also described. The synthesis of 7-amino-8-fluoro[1]benzothieno[3,2-d]pyrimid-4(3H)-one was relatively straightforward, but synthesis of the corresponding 7-amino-8-protio analogue proved to be very difficult, and required several approaches before a successful one was found.

Relaxation of smooth muscle in a mammal

4-Amino-6-arylpyrimidines and salts thereof, a novel class of inhibitors of platelet aggregation and broncho-dilators in mammals, and 4-hydroxy-6-arylpyrimidines as useful intermediates.